Recently, astrocyte-derived IL-11 has been demonstrated to upregulate PD-L1 expression and promote immune escape in NSCLC by reducing T lymphocytes demonstrating direct immunomodulating effects of IL-11 and a potential therapeutic target [49]. The gene discussed is IL11; the disease is non-small cell lung carcinoma.